FLH Partner Brian J. Malkin Speaks at ACI’s Orphan Drugs and Rare Diseases on November 29, 2012 in Boston

Frommer Lawrence & Haug LLP Partner Brian J. Malkin will present on “Mastering the Intricacies of the Orphan Drug Designation Process: A Step-by-Step Guide to Navigating the Pathway” on November 29, 2012. Mr. Malkin’s presentation is part of ACI’s inaugural conference, “Orphan Drugs and Rare Diseases: Maximizing Opportunities and Overcoming Stumbling Blocks in the Designation and Development Process” in Boston, Massachusetts from November 28-29, 2012. Mr. Malkin’s presentation will include how to assess whether a compound/indication qualifies for orphan drug designation, what benefits may be achieved by obtaining an orphan drug designation prior to product/indication approval, and how to respond to a rejection for an orphan drug designation request, including demonstrating clinical superiority. For more information, see here.